Taysha Gene Therapies, Inc. stock is down -24.36% since 30 days ago. The next earnings date is Mar 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 3 December’s closed higher than November. In the last 4 Unusual Options Trades, there were 4 PUTs. 100% of analysts rate it a buy.
Taysha Gene Therapies, Inc. focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company was incorporated in 2019 and is based in Dallas, Texas.